Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis.

被引：3
|
作者：
Goff, L. W.
Cohen, R. B.
Berlin, J.
Noberasco, C.
Borghaei, H.
Gallo-Stampino, C.
Wang, E.
Lowe, D. Hu
Levin, W. J.
De Braud, F. G.
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] European Inst Oncol, Milan, Italy
[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[6] Pfizer Oncol, Milan, Italy
[7] Pfizer Oncol, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3009
引用
收藏
页数：1
相关论文
共 45 条
  • [41] A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results.
    Kuenen, B.
    Witteveen, E.
    Ruijter, R.
    Ervin-Haynes, A.
    Tjin-A-ton, M.
    Fox, F.
    Ding, C.
    Giaccone, G.
    Voest, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 126S - 126S
  • [42] A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule
    Hidalgo, M.
    Gomez, M. Tirado
    Lewis, N.
    Vuky, J. L.
    Taylor, G.
    Hayburn, J. L.
    Hsu, K.
    Kosh, M.
    Picozzi, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors
    Spratlin, Jennifer L.
    Eckhardt, S. Gail
    Gore, Lia
    Camidge, D. Ross
    Leong, Stephen
    O'Bryant, Cindy
    Diab, Sami
    Chow, Laura Q. M.
    Youssoufian, Hagop
    Fox, Floyd
    Cohen, Roger B.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3346S - 3346S
  • [44] A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN).
    Bastholt, L
    Specht, L
    Jensen, K
    Brun, E
    Loft, A
    Petersen, J
    Kastberg, H
    Eriksen, JG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 507S - 507S
  • [45] A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer
    Ray-Coquard, Isabelle
    Haluska, Paul
    O'Reilly, Seamus
    Cottu, Paul H.
    Elit, Lorraine
    Provencher, Diane M.
    Beckmann, Matthias W.
    Bosserman, Linda D.
    Jacod, Sylvie
    Houe, Vincent
    Loberg, Robert D.
    Glaspy, John A.
    Karlan, Beth
    Slamon, Dennis J.
    Konecny, Gottfried E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345